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Objective: Central serous chorioretinopathy (CSC), a specific form of macular 
degeneration, has been reported as presenting manifestation of Cushing’s syndrome. 
Furthermore, CSC has been associated with both exogenous hypercortisolism and 
endogenous Cushing’s syndrome. It is important to know whether CSC patients should 
be screened for Cushing’s syndrome. Although hypothalamic-pituitary-adrenal (HPA) 
axis hyperactivity in CSC has been suggested, no detailed evaluation of the HPA axis 
has been performed in a large cohort of CSC patients. This study aimed to investigate 
whether Cushing’s syndrome prevalence is increased among chronic CSC (cCSC) 
patients and whether detailed endocrinological phenotyping indicates hyperactivity of 
the HPA axis.
Design: Cross-sectional study.
Patients: 86 cCSC patients and 24 controls.
Measurements: Prevalence of Cushing’s syndrome, HPA axis activity.
results: None of the cCSC patients met the clinical or biochemical criteria of Cushing’s 
syndrome. However, compared to controls, HPA axis activity was increased in cCSC 
patients, reflected by higher 24 h urinary free cortisol, and accompanying higher waist 
circumference and diastolic blood pressure, whereas circadian cortisol rhythm and feed-
back were not different. Chronic CSC patients did not report more stress or stress-related 
problems on questionnaires.
conclusion: No case of Cushing’s syndrome was revealed in a large cohort of cCSC 
patients. Therefore, we advise against screening for Cushing’s syndrome in CSC patients, 
unless additional clinical features are present. However, our results indicate that cCSC is 
associated with hyperactivity of the HPA axis, albeit not accompanied with perception of 
more psychosocial stress.
Keywords: central serous chorioretinopathy, cortisol, cross-sectional study, cushing’s syndrome, hypercortisolism, 
hypothalamic–pituitary–adrenal axis, psychosocial stress
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inTrODUcTiOn
Cushing’s syndrome is a rare disease characterized by exces-
sive exposure to cortisol and is associated with both metabolic 
and behavioral abnormalities. The clinical manifestation may 
vary, and in addition to well-known features like facial round-
ing, truncal obesity, and dorsal fat pad (1), ophthalmological 
abnormalities also occur. We recently reported patients who 
developed visual symptoms caused by chronic central serous 
chorioretinopathy (cCSC) as presenting manifestation of 
Cushing’s syndrome (2).
Central serous chorioretinopathy (CSC) is a relatively com-
mon eye disease often affecting the macula, in which choroidal 
congestion, thickening, and hyperpermeability lead to retinal 
pigment epithelial damage and cause serous subretinal fluid 
accumulation. Persistent neuroretinal detachments in untreated 
cCSC may result in irreversible photoreceptor damage, which 
may lead to permanent visual loss and decreased quality of 
life (3, 4).
The association of CSC with both exogenous steroids and 
endogenous hypercortisolism has been reported (2, 5, 6). 
Although no data are available on the prevalence of CSC in 
patients treated with corticosteroids, up to 52% of CSC patients 
in different cohorts reported to use steroids during the active 
phase of disease (6, 7). Higher endogenous cortisol levels were 
reported in 30 patients with acute CSC (8), and 24  h urinary 
free cortisol (UFC) was higher among 16 patients with chronic 
CSC compared to controls (9). However, clinical characteristics, 
circadian tests, and cortisol feedback were not included in these 
studies, making it impossible to conclude on the prevalence of 
Cushing’s syndrome.
In addition, psychosocial stress has been described in rela-
tion to CSC. Different studies reported associations between 
psychosocial stressful events and CSC, especially in patients with 
poor coping mechanisms (10). People with type A personality 
characteristics have been suggested to be at higher risk for the 
development of CSC (11).
In view of the suspected relationship between overactivity 
of the hypothalamic–pituitary–adrenal (HPA) axis and CSC, a 
relevant question is whether CSC patients should be screened 
for Cushing’s syndrome. Therefore, we conducted a systematic 
screening for the presence of Cushing’s syndrome in a large 
cohort of cCSC patients, using detailed clinical and biochemical 
evaluation of the HPA axis, and compared the latter to a control 




Cross-sectional study with the following key objectives: to assess 
the prevalence of Cushing’s syndrome in cCSC patients and to 
assess whether cCSC is associated with hyperactivity of the HPA 
axis. If this second aim was confirmed, we aimed to explore the 
association between HPA axis hyperactivity and psychosocial 
stress in cCSC.
study Population
Eighty-six consecutive cCSC patients, who were followed at the 
Department of Ophthalmology at our tertiary referral center, were 
screened. The cCSC diagnosis had been confirmed by fundoscopy, 
digital color fundus photography (Topcon Corp., Tokyo, Japan), 
fundus autofluorescence (Spectralis HRA  +  OCT; Heidelberg 
Engineering, Heidelberg, Germany), spectral-domain optical 
coherence tomography (Spectralis HRA  +  OCT), fluorescein 
angiography (Spectralis HRA +  OCT), and indocyanine green 
angiography (Spectralis HRA  +  OCT), according to current 
standard (5, 12–16). Patients diagnosed with acute CSC (focal 
leakage spot or a smokestack pattern on fluorescein angiography) 
were excluded (5, 12–16). No evidence of other retinal diagnoses 
had to be present.
Other exclusion criteria possibly affecting the evaluation of the 
HPA axis were use of corticosteroids/sleep medication prior to 
the development or during the time course of cCSC, excessive 
alcohol intake (>21 U/week), nightshift work, or traveling from 
another time zone in the 6 weeks before evaluation.
We also performed tests for hypercortisolism in a set of gen-
der-matched controls. Thirty-eight healthy subjects responded 
to advertisements. Fourteen were excluded based on criteria 
described below. A total of 24 healthy gender-matched control 
subjects were eligible for inclusion (inclusion period: September 
2015 to December 2016). Exclusion criteria were (familial) 
history of eye diseases/visual problems, psychiatric diseases, or 
chronic physical diseases possibly influencing endocrinological 
screening, corticosteroids/antidepressants/sleep medication use, 
excessive alcohol intake (>21 U/week), recent weight loss/gain 
of >10%, and working nightshifts or traveling from another time 
zone in the 6 weeks before evaluation.
Written informed consent was obtained from all participants 
and approval of the institutional review board and the ethics 
committee was obtained (NL50816.058.14).
endocrinological evaluation
Screening was performed including a detailed medical history, 
complete physical examination, and biochemical analysis. The 
physical examination consisted among others of the evaluation of 
clinical Cushing stigmata and was performed by two physicians 
(FH/MB).
For evaluating HPA axis activity, all three commonly available 
screening tests were performed: UFC in two 24 h urine samples, 
midnight salivary cortisol (mSC), and 1  mg dexamethasone 
overnight suppression test. Healthy controls were subjected to 
one 24 h urine and one midnight saliva collection only. In case 
of deviant test results, participants were re-tested to exclude 
relevant pathology. The first test results were included in the 
analysis. UFC (82 patients and all controls) was analyzed using 
an in-house LC-tandem MS method, calibrated using Cerilliant 
certified reference material C-106, cortisol 1  mg/ml in metha-
nol. The analytical variation was between 6.5 and 5% for urine 
cortisol levels between 50 and 900 nmol/L. Cortisol levels below 
150 nmol/24 h were considered normal. Serum (81 patients) and 
salivary cortisol (82 patients and 23 controls) were analyzed using 
a Roche ECLIA Cortisol assay (second generation) on a Modular 






Age, years 48.74 (10.84) 41.08 (13.08) 0.004
Sex, male/female 77/9 19/5 0.182
Duration of cCSC disease,  
years (range)
3.86 (0.17–37.06) – –
History of hypertension, n (%) 23 (26.7%) 1 (4.2%) 0.023a
History of diabetes mellitus, n (%) 6 (7.0%) 0 (0.0%) 0.336
History of dyslipidemia, n (%) 18 (20.9%) 1 (4.2%) 0.068
History of psychiatric  
disorders,bn (%)
16 (18.6%) 1 (4.2%) 0.113
History of thromboembolic  
events, n (%)
0 (0%) 0 (0%) –
History of cardiac events,cn (%) 5 (5.9%) 2 (8.3%) 0.648
History of sexual disorders,dn (%) 19 (22.1%) 1 (4.2%) 0.069
Systolic blood pressure, mmHg 135.41 (16.64) 129.75 (12.41) 0.143
Diastolic blood pressure, mmHg 82.94 (10.30) 77.29 (12.36) 0.006
Body mass index 26.15 (3.59) 24.92 (3.14) 0.096
Waist circumference, cm 92.74 (11.07) 86.42 (9.28) 0.011
Waist–hip ratio 0.95 (0.07) 0.90 (0.06) 0.003
Moon face, n (%) 1 (1.2%) 0 (0.0%) 1.000
Dorsal fat pad, n (%) 1 (1.2%) 0 (0.0%) 1.000
Purple striae, n (%) 0 (0.0%) 0 (0.0%) –
Muscle weakness, n (%) 3 (3.5%) 0 (0.0%) 1.000
Active skin infections, n (%) 2 (2.3%) 0 (0.0%) 1.000
Hematomas, n (%) 3 (3.5%) 1 (4.2%) 1.000
Ankle edema, n (%) 2 (2.3%) 0 (0.0%) 1.000
Data are presented as mean (SD) or as numbers, unless specified otherwise.
aNot statistically significant after correction for age.
bConsisting of depression, anxiety or panic disorder, posttraumatic stress disorder, 
burn-out, alcohol abuse, and schizophrenia.
cConsisting of myocardial infarction, endocarditis, and atrial fibrillation.
dConsisting of impotence, hirsutism, menstrual cycle disorders, and loss of libido.
cCSC, chronic central serous chorioretinopathy.
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E170 immunoanalyser (Roche Holding AG, Basel, Switzerland). 
Analytical variation ranged between 10.1 and 1.9% for serum 
cortisol levels between 3.6 and 1,660 nmol/L and between 14.2 
and 2.5% for saliva cortisol levels between 2.6 and 78  nmol/L. 
Cortisol levels below 1.5  nmol/L could not be determined. In 
midnight saliva, cortisol levels below 5.7 nmol/L were considered 
normal. The cutoff limit for the dexamethasone suppression test 
was 50 nmol/L (17).
Questionnaires
Perceived Stress Scale (PSS)
The PSS developed by Cohen et  al. was designed to measure the 
intensity of perceived stress and considers the degree to which 
individuals experience their lives as unpredictable, uncontrollable, 
and overloading (18). The original scale contained 14 items, but its 
creators refined it to 10 items, of which four are positively and six are 
negatively phrased (19). Items are coded from 0 to 4 and summed to 
compute a total score. Higher scores indicate greater perceived stress. 
Scores around 13 on the PSS are considered average, whereas high 
stress groups have reported scores of approximately 20 points (19).
Stress Thermometer
A visual analog scale was designed by the authors to measure 
the amount of stress experienced in the week before evaluation. 
Individuals rate their amount of stress on a scale from 0 to 10, 
with 0 indicating “no stress at all” and 10 indicating “the highest 
possible amount of stress.”
Insomnia Severity Index
This seven-item scale assesses self-reports of insomnia symptoms 
over the last 2 weeks. The items are scored on a scale from 0 to 
4. Total scores of 0 to 7 are categorized as “no insomnia,” scores 
from 8 to 14 are considered to indicate “sub-threshold insomnia,” 
scores from 15 to 21 are indicative of “moderate insomnia,” and 
scores from 22 to 28 are considered “severe insomnia” (20).
Brugha Questionnaire on Life Events
This list to assess the occurrence of stressful events includes 12 
life events that were found to have long-term negative effects on 
most people who experience them. Participants indicate whether 
certain events have occurred to them during the past year or 
earlier in their lives (21).
statistical analysis
Based on data derived from a recent study by Aranda and col-
leagues (22), a power calculation was performed on the difference 
in 24 h UFC deemed relevant to detect (20 nmol/24 h). To detect 
such a difference (with power 80% and alpha 0.05), a sample size 
of 54 cCSC patients and 18 healthy controls would suffice.
Data were analyzed using SPSS Statistics (version 23; IBM 
Corp., Armonk, NY, USA). Data were presented as mean and SD, 
unless mentioned otherwise. The primary analyses comprised: (1) 
prevalence of Cushing’s syndrome in cCSC and (2) comparison of 
biochemical results between cCSC patients and healthy controls. 
Because the majority of cCSC patients were males (in line with 
other cohorts described in literature), a male-only sensitivity 
analysis was performed. Mean and SD scores for each question-
naire were calculated.
Normality of data was tested using the Shapiro–Wilk test. All 
normally distributed data were analyzed using independent sam-
ple t-tests. Data with a non-normal distribution were analyzed 
by means of nonparametric independent sample tests. The two 
groups were compared using a general linear model, correcting 
for potential confounders such as age, waist–hip ratio, and waist 
circumference. Associations were assessed using linear regression 
analyzes. The level of significance was set at P  =  0.05. For the 
analysis of the questionnaires, the level of significance was set at 
P = 0.01 to correct for multiple testing.
After reassessment of the retinal imaging by two  independent 
ophthalmologists, five patients considered to have less typical 
cCSC findings on imaging were excluded from analysis. Moreover, 




Eighty-six cCSC patients (77 males) and 24 healthy controls (19 
males) were included (Table 1). The gender distribution was in 
TaBle 2 | Biochemical characteristics of participants.
ccsc patients controls P value
Urinary free cortisol, nmol/24 ha 83.99 (49.04) 51.55 (28.49) 0.000
Detectable midnight salivary 
cortisol,a,b %
24.4 60.9 0.002
Serum cortisol after 1 mg Dexa, 
μmol/La







Urinary free cortisol, nmol/24 ha 78.44 (38.63) 95.30 (64.76) 0.524
Detectable midnight salivary 
cortisol,a %
27.3 18.5 0.428
Serum cortisol after 1 mg Dexa, 
μmol/La
0.028 (0.045) 0.031 (0.041) 0.855
Data are presented as mean (SD) or as numbers, unless specified otherwise.
aNumber of participants.
Urinary free cortisol: 82 cCSC patients (55 active cCSC patients, 27 inactive CSC 
patients) and 24 controls.
Midnight salivary cortisol: 82 cCSC patients (55 active cCSC patients, 27 inactive CSC 
patients) and 23 controls.
Serum cortisol after 1 mg dexamethasone: 55 active cCSC patients, 26 inactive CSC 
patients.
b>1.5 nmol/L.
cCSC, chronic central serous chorioretinopathy; Dexa, dexamethasone.
FigUre 2 | UFC levels in active cCSC patients and inactive cCSC patients. 
Data presented as individual values and mean. Active cCSC patients n = 55; 
inactive cCSC patients n = 27. Abbreviations: UFC, urinary free cortisol; 
cCSC, chronic central serous chorioretinopathy.
FigUre 1 | UFC levels in cCSC patients and healthy controls. Notes: Data 
presented as individual values and mean. Patients n = 82; controls n = 24. 
Abbreviations: UFC, urinary free cortisol; cCSC, chronic central serous 
chorioretinopathy.
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line with available literature (5, 15). The mean duration of disease 
at the time of evaluation was 3.86 years (range 0.17–37.06). Fifty-
eight patients had active CSC (presence of subretinal fluid) at the 
moment of screening.
There was no difference in gender distribution or body mass 
index between the two groups. Patients were 7.5 years older than 
controls.
clinical evaluation
None of the cCSC patients presented with a combination of 
clinical signs and symptoms typical for Cushing’s syndrome. 
Hypertension was reported by 27% of patients and one control 
(4%, P = 0.023). In addition, cCSC patients had a higher preva-
lence of other comorbidities, e.g., dyslipidemia and psychiatric 
disorders (see Table  1). Waist circumference, waist–hip ratio, 
and diastolic blood pressure were higher in patients compared to 
controls, despite a higher prevalence of ongoing antihypertensive 
medication use in the patient group. These differences remained 
significant after adjustment for age. Characteristic Cushing fea-
tures were rare among cCSC patients.
hormonal evaluation
Clinical Evaluation of Patients
None of the cCSC patients had Cushing’s syndrome, but several 
patients demonstrated an abnormally high cortisol value in 
one or more of the screening tests (Table  2). Increased UFC 
(>150 nmol/24 h, average of two portions) was present in seven 
patients, in whom repeated testing revealed normal values. 
Increased mSC levels (>5.7 nmol/L, average of two portions) was 
observed in three patients, which normalized upon retesting in 
two and persisted to be slightly elevated in one patient. Insufficient 
suppression after dexamethasone was observed in four patients. 
Retesting revealed normal test results in one patient. In the absence 
of other biochemical and clinical features of Cushing’s syndrome, 
we concluded that the abnormal test results in the other patients 
were likely due to intervening medication (antidepressants, 
gonadotropin-releasing hormone analogs, covert stimulant use). 
Furthermore, normal lipid profiles, no elevated inflammation 
parameters, and no hypokalemia were detected (data not shown).
Comparison with Healthy Controls
Mean UFC levels were higher in cCSC patients, compared to 
controls (Figure  1). This difference remained after correction 
for age (P  =  0.001), age, and waist–hip ratio (P  =  0.002), age 
and comorbidities (e.g., psychiatric disorders, diabetes mellitus, 
hypertension, obesity; P = 0.011), and when males were evaluated 
solely (P = 0.001).
Nonparametric analysis revealed that non-detectable mSC 
was present in 76% of cCSC patients compared to 39% of healthy 
controls (P  =  0.002), with a similar difference in a male-only 
analysis (72 versus 33%, P = 0.001). Three patients (4%) showed 
abnormally elevated mSC, compared to two controls (9%). The 
other participants’ mSC levels were between 1.5 and 5.7 nmol/L.
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HPA Axis at Different cCSC Disease Stages
Hypothalamic–pituitary–adrenal axis activity was not different 
between patients with active and inactive cCSC. Mean UFC 
levels were 78.44 (SD 38.63) versus 95.30 (SD 64.76), respectively 
(P = 0.524, Figure 2), and mSC was detectable in 27% of patients 
with active disease versus 19% of patients with inactive disease 
(P = 0.386).
The exclusion of five atypical cCSC patients or the exclusion 
of one outlier in UFC did not affect any of the described results. 
Clustered analysis did also not significantly change the aforemen-
tioned results (data not shown).
Questionnaire analysis
Perceived Stress Scale
Chronic CSC patients (n = 81, 94%) reported a mean total score of 
12.95 (SD 5.82, range 0–30). After correction for multiple testing, 
no significant difference in PSS score was found between cCSC 
patients with active disease compared to inactive patients (mean 
11.89 versus 15.07, P = 0.019). Furthermore, no association was 
found between UFC level and the total score in patients (β = 2.04, 
P = 0.032, R2 = 0.06).
Stress Thermometer
Eighty-three cCSC patients (96%) scored their amount of expe-
rienced stress in the week prior to evaluation, reporting a mean 
score of 4.4 (range 0–10). In addition, no differences were found 
when active patients were compared to patients with inactive 
disease, and no association between UFC level and score on this 
scale was found (β = 0.71, P = 0.742, R2 = 0.001).
Insomnia Severity Index
Total scores were calculated for 83 cCSC patients (mean 6.54, range 
0–24). The mean score was categorized as “no clinical significant 
insomnia.” When insomnia was scored as a “yes or no” variable, 
11% of patients scored either moderate or severe insomnia. There 
was no difference in presumed insomnia between active patients 
and inactive patients, and no association between UFC levels and 
Insomnia Severity Index scores was found (β = −0.97, P = 0.378, 
R2 = 0.010).
Brugha Questionnaire on Life Events
Thirty out of 83 patients (36%) reported serious life events in 
the past year. Twenty-four hour UFCs were not higher in these 
patients compared to the patients with no serious life event in 
the preceding year. Disease activity did not affect the report of 
serious life events in the past year (P = 1.000). The type of life 
events experienced, however, was different, with active patients 
reporting more experiences with serious illness or violence of a 
near relative, whereas inactive patients more often reported the 
same experiences earlier in live.
Associations of Questionnaire Outcomes and 
Cortisol
Analyses performed with exclusion of the five atypical cCSC 
patients and analyses with exclusion of the UFC outlier did not 
significantly change the aforementioned results.
DiscUssiOn
This is the first study that systematically evaluated various aspects 
of the activity of the HPA axis in a large cohort of cCSC patients. 
Whereas we did not find any case of Cushing’s syndrome, the 
activity of the HPA axis appeared to be increased in cCSC patients, 
without disruption of circadian rhythm. This was reflected by 
significantly higher 24  h UFCs, increased waist circumference, 
and diastolic blood pressure, but normal mSC levels. Our study 
demonstrates that systematic screening of all cCSC patients for 
the presence of Cushing’s syndrome is not indicated.
In the present study, we have screened a large patient cohort 
in detail, combining all currently available biochemical screening 
tests with a detailed clinical phenotyping. We found significantly 
higher 24 h UFC levels in cCSC patients, albeit within the normal 
reference range, with preservation of normal diurnal  rhythmicity. 
Elevated UFC levels have been reported previously in a small 
cohort of acute CSC patients during hospital admission, when 
compared to patients with acute retinal detachment (8), and in 
a small cohort of cCSC patients that were compared to age- and 
sex-matched controls (9), though data on demographics of these 
participants were lacking.
In contrast to earlier studies suggesting an association between 
cCSC and psychosocial stress, we did not find a clear relation-
ship between cCSC activity and stress, based on the results of 
four stress questionnaires. In addition, no association was found 
between HPA axis activity and psychosocial stress. A critical 
evaluation of the available literature does not support a clear 
association between cCSC and stress: Conrad et al. demonstrated 
no increased exposure to critical life events in 30 CSC patients 
and reported other findings suggestive of difficulties in emotional 
regulation (23). Other studies reported an association between 
stress, severe stressful events, and CSC, especially in patients 
with poor coping mechanisms (10, 24, 25), but the provided 
information on how stress was measured was very limited, cir-
cumstantial, or even absent. Our patients scores (on the PSS) did 
not differ from reported average scores and were not comparable 
with scores reported by high stress groups (19). In addition, our 
patients with active cCSC reported no difference in experienced 
life events, insomnia (as an expression of stress) or perceived 
stress on two different scales, indicating that cCSC activity is not 
associated with psychosocial stress.
Both endogenous hypercortisolism and exogenous administra-
tion of corticosteroids are related to CSC (2, 5, 6, 9). Occurrence of 
one or more episodes of CSC has previously been described in 5% 
of 60 patients with active endogenous hypercortisolism. All these 
CSC patients had been diagnosed with pituitary adenoma (26). 
Fundus characteristics resembling CSC have also been reported 
in patients with Cushing’s disease (27). Moreover, in a patient 
with hypercortisolism due to adrenocortical carcinoma, bilateral 
CSC has been found (28). Several underlying mechanisms have 
been hypothesized. Endogenous hypercortisolism increases 
platelet aggregation leading to microthrombi and increased blood 
viscosity, which could be of importance in the pathogenesis of 
CSC (29). Hypercortisolism has also been associated with cho-
roidal fragility and hyperpermeability (30). Moreover, increased 
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transcription of adrenergic receptors has been correlated with 
CSC (31). In addition, a role for the mineralocorticoid pathway 
has been suggested by recent studies in rats and by findings in 
CSC patients treated with mineralocorticoid receptor antagonists 
(eplerenone or spironolactone) (15, 32). Both glucocorticoids 
and mineralocorticoids activate the mineralocorticoid recep-
tor expressed on choroidal endothelial cells. Activation of the 
mineralocorticoid receptor, via upregulation of the endothelial 
vasodilatory calcium-dependent potassium channel KCa2.3 by 
hyperpolarization of these endothelial cells and of smooth muscle 
cells, has been suggested to lead to vasodilation (15).
Our study also has limitations. The cross-sectional character 
does not allow drawing conclusions on any causal relationship. 
Furthermore, a reversed causation (cCSC as a trigger for activa-
tion of the HPA axis) seems to be less likely in light of the cur-
rently available literature, yet is not ruled out. Also, the number of 
healthy control subjects recruited via advertisements was limited, 
and because our study was not powered for the questionnaire 
outcomes, we did not compare patient and control data. Only one 
24 h urine sample was collected by healthy controls. Volume and 
creatinine level analyses confirmed adequate collection of these 
single samples. The fact that 24 h UFC is higher in the presence of 
equal results of mSC can very well be explained by an increased 
activity of the HPA axis with preservation of normal diurnal 
rhythmicity (in contrast to the “autonomous” cortisol secretion 
that is characterized by loss of diurnal rhythmicity). The absence 
of associations between UFC level and either cCSC activity or 
outcomes of stress questionnaires in our study may appear to be 
contradictory to the conclusion that the HPA axis is more acti-
vated in cCSC patients. Nonetheless, one should keep in mind 
that there is a wide individual variation in normal cortisol levels 
and in cortisol receptor activation thresholds, leading to different 
thresholds for the development of cortisol-related symptoms and 
pathology. Together, this may explain why the HPA axis could still 
be activated in cCSC patients despite the absence of an associa-
tion between UFC and cCSC activity or questionnaire outcomes 
in our patient population.
Although CSC has been described to be a presenting symp-
tom of Cushing’s syndrome and these diseases are known to 
sporadically co-exist (2), our results argue against screening 
for endogenous hypercortisolism in all cCSC patients. Since 
the interpretation of the available biochemical screening tests 
in light of the clinical features is challenging and in order to 
minimize the risk of false positive test results, screening should 
be reserved for those cCSC patients in whom clinical signs or 
symptoms raise suspicion of Cushing’s syndrome. Only then 
patients should be referred to an endocrinologist for evaluation 
of the HPA axis. In dealing with Cushing’s syndrome patients, 
endocrinologists also need to be aware of the potential coexist-
ence of CSC.
In conclusion, systematic screening of all patients with cCSC 
for Cushing’s syndrome is not indicated. However, the activity 
of the HPA axis appears to be increased, with preservation of 
circadian rhythm. Finally, in contrast to earlier ideas, we did 
not find obvious associations between cCSC, cCSC activity, and 
psychosocial stress. The observed hyperactivity of the HPA axis 
confirms the previously reported association between cortisol 
and CSC and merits further studies to unravel the underlying 
pathophysiological mechanisms.
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